AR093840A1 - Derivados de bencimidazol como antagonistas de ep4 - Google Patents
Derivados de bencimidazol como antagonistas de ep4Info
- Publication number
- AR093840A1 AR093840A1 ARP130104542A ARP130104542A AR093840A1 AR 093840 A1 AR093840 A1 AR 093840A1 AR P130104542 A ARP130104542 A AR P130104542A AR P130104542 A ARP130104542 A AR P130104542A AR 093840 A1 AR093840 A1 AR 093840A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- alkoxy
- mono
- polysubstituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Abstract
Reivindicación 1: Compuestos de la fórmula general (1) en donde R¹ᵃ, R¹ᵇ representan, de modo independiente entre sí, H, alquilo C₁₋₅, alquenilo C₂₋₅, alquinilo C₂₋₅, cicloalquil C₃₋₆-(CH₂)ₘ, heterocicloalquil C₃₋₆-(CH₂)ₙ, alcoxi C₁₋₅-alquilo C₁₋₃, cicloalcoxi C₃₋₆-alquilo C₁₋₃, amino-alquilo C₁₋₃, alquil C₁₋₅-amino-alquilo C₁₋₃, dialquil C₁₋₅-amino-alquilo C₁₋₃ o ciano, en donde la unidad heterocíclica opcionalmente existente está seleccionada con preferencia del grupo compuesto por oxetano, tetrahidrofurano, tetrahidropirano, 1,4-dioxano, morfolina, azetidina, pirrolidina, piperazina y piperidina y en donde los radicales de alquilo, cicloalquilo o heterocicloalquilo opcionalmente existentes pueden estar mono- o polisustituidos, igual o diferente con halógeno, alquilo C₁₋₅, hidroxi, carboxi, carboxi-alquilo C₁₋₅, alcoxi C₁₋₅-carbonil-alquilo C₁₋₅ o alquil C₁₋₅-sulfonilo; R⁴ representa H, F, Cl, alquilo C₁₋₂, cicloalquilo C₃₋₅, alcoxi C₁₋₂ o cicloalquil C₃₋₄-metilo en donde la correspondiente unidad de alquilo o cicloalquilo puede estar mono- o polisustituida, igual o diferente, con halógeno o hidroxi; A representa H, alquilo C₁₋₃, Br, heterociclilo de 4 - 6 miembros, formilo, RO-CO(CH₂)ₚ, R⁵,R⁵N-CO(CH₂)ₚ, carboximetoxi, ROSO₂(CH₂)ₚ, R⁵R⁵N-SO₂(CH₂)ₚ, alquil C₁₋₆-sulfonilo, alquil C₁₋₆-sulfonimidoilo, cicloalquil C₃₋₆-sulfonimidoilo o ciano, en donde R representa H, alquilo C₁₋₇, cicloalquilo C₃₋₇, fenil-(CH₂)q o alcoxi C₁₋₇-alquilo C₁₋₅ y una unidad heterocíclica opcionalmente existente está seleccionada con preferencia del grupo compuesto por pirazol, imidazol, triazol, tetrazol, oxazol, isoxazol y oxadiazol y una unidad de alquilo contenida puede estar mono- o polisustituida, igual o diferente, con halógeno o hidroxi y una unidad heterocíclica opcionalmente contenida o el fenilo puede estar mono- o polisustituido con alquilo C₁₋₃, trifluorometilo o hidroxi; R⁵, R⁵ de modo independiente entre sí, H, alquilo C₁₋₇, alcoxi C₁₋₇, alcoxi C₁₋₇-alquilo C₂₋₅, heterocicloalquil C₃₋₆-(CH₂)ʳ, alquil C₁₋₇-carbonilo, cicloalquil C₃₋₇-carbonilo, aril-(CH₂)ʳ-carbonilo, piridil-(CH₂)ʳ-carbonilo, alquil C₁₋₇-sulfonilo, cicloalquil C₃₋₇-sulfonilo o aril-(CH₂)ʳ-sulfonilo, en donde arilo es fenilo o naftilo, o representa piridil-(CH₂)ʳ-sulfonilo, y una unidad heterocíclica opcionalmente contenida está seleccionada con preferencia del grupo compuesto por oxetano, tetrahidrofurano, tetrahidropirano, 1,4-dioxano, morfolina, azetidina, pirrolidina, piperazina y piperidina y en donde R⁵ y R⁵ pueden estar opcionalmente mono- o polisustituidos, igual o diferente, con alquilo C₁₋₂, trifluorometilo, halógeno, alquil C₁₋₅-amino, dialquil C₁₋₅-amino, alcoxi C₁₋₂, trifluorometoxi o hidroxi, o R⁵, R⁵ junto con el átomo de nitrógeno al que están unidos, forman un anillo heterocíclico de 4 - 6 miembros opcionalmente con otro heteroátomo, que están seleccionados del grupo compuesto por O y N, y que puede estar opcionalmente mono- o polisustituido, igual o diferente, con oxo, hidroxi, carboxi, alquilo C₁₋₂ o alcoxi C₁₋₂; m es 0, 1, 2 ó 3; n es 0, 1, 2 ó 3; p es 0, 1 ó 2; q es 1, 2 ó 3; r es 0, 1, 2 ó 3; y B está seleccionado de las estructuras del grupo de fórmulas (2); R⁶ representa H, F, Cl, CH₃, CF₃, CH₃O o CF₃O; R⁷, R⁸ representan en cada caso, de modo independiente entre sí, H, F, Cl, ciano, SF₅, alquilo C₁₋₃, cicloalquilo C₃₋₅, alcoxi C₁₋₂ o cicloalquil C₃₋₄-metilo, en donde la correspondiente unidad de alquilo o cicloalquilo puede estar mono- o polihalogenada; y R⁹ representa alquilo C₁₋₅, alquenilo C₂₋₅, alquinilo C₂₋₅, cicloalquil C₃₋₆-(CH₂)ₙ, heterocicloalquil C₃₋₆-(CH₂)ₙ, o alcoxi C₁₋₇-alquilo C₂₋₅, en donde la unidad heterocíclica opcionalmente existente está seleccionada del grupo compuesto por oxetano, tetrahidrofurano, tetrahidropirano, morfolina, pirrolidina y piperidina y en donde las unidades de alquilo, cicloalquilo o heterocicloalquilo opcionalmente existentes pueden estar mono- o polisustituidas, igual o diferente, con halógeno, alquilo C₁₋₂, alcoxi C₁₋₂ o carboxi; y sus isómeros, diastereómeros, enantiómeros, solvatos y sales o clatratos de ciclodextrina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12195849 | 2012-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093840A1 true AR093840A1 (es) | 2015-06-24 |
Family
ID=47325927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104542A AR093840A1 (es) | 2012-12-06 | 2013-12-06 | Derivados de bencimidazol como antagonistas de ep4 |
Country Status (41)
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2782584T (lt) | 2011-11-23 | 2021-09-10 | Therapeuticsmd, Inc. | Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9492460B2 (en) * | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| US10053454B2 (en) | 2013-02-27 | 2018-08-21 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| KR20160060660A (ko) | 2013-10-01 | 2016-05-30 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 친화성 크로마토그래피를 위한 및 치료제의 반감기를 연장시키기 위한 화합물 |
| TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| MA39211B1 (fr) * | 2013-12-24 | 2019-01-31 | Bristol Myers Squibb Co | Composés tricycliques comme agents anti-cancers |
| US9458156B2 (en) | 2014-12-23 | 2016-10-04 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| CN104326937B (zh) | 2014-09-03 | 2016-08-24 | 天津市肿瘤研究所 | 抗肿瘤化合物及其医药用途 |
| SG10201913603QA (en) | 2014-10-06 | 2020-02-27 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| US9725449B2 (en) | 2015-05-12 | 2017-08-08 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| PL3436446T3 (pl) | 2016-03-31 | 2023-09-11 | Vertex Pharmaceuticals Incorporated | Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| LT3519401T (lt) | 2016-09-30 | 2021-11-25 | Vertex Pharmaceuticals Incorporated | Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas |
| US10793547B2 (en) | 2016-12-09 | 2020-10-06 | Vertex Pharmaceuticals Incorporated | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| WO2018162562A1 (en) * | 2017-03-10 | 2018-09-13 | Bayer Pharma Aktiengesellschaft | Use of an ep4 antagonist for the treatment of inflammatory pain |
| AU2018269666B2 (en) | 2017-05-18 | 2022-02-03 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as PGE2 receptor modulators |
| KR102612649B1 (ko) | 2017-05-18 | 2023-12-11 | 이도르시아 파마슈티컬스 리미티드 | Pge2 수용체 조절제로서의 벤조푸란 및 벤조티오페논 유도체 |
| US11839613B2 (en) | 2017-05-18 | 2023-12-12 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
| EP3625224B1 (en) | 2017-05-18 | 2021-08-04 | Idorsia Pharmaceuticals Ltd | N-substituted indole derivatives |
| CA3063788A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CA3069226A1 (en) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CN111051280B (zh) | 2017-08-02 | 2023-12-22 | 弗特克斯药品有限公司 | 制备吡咯烷化合物的方法 |
| WO2019038156A1 (en) | 2017-08-22 | 2019-02-28 | Bayer Pharma Aktiengesellschaft | USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS |
| CA3078893A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
| JP7245834B2 (ja) | 2017-12-08 | 2023-03-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| WO2020014445A1 (en) * | 2018-07-11 | 2020-01-16 | Arrys Therapeutics, Inc. | Ep4 inhibitors and synthesis thereof |
| CN113527206B (zh) * | 2020-04-17 | 2022-12-30 | 上海中泽医药科技有限公司 | 一种苯并氮杂环类化合物、其制备方法及用途 |
| KR20230107228A (ko) | 2020-11-13 | 2023-07-14 | 오노 야꾸힝 고교 가부시키가이샤 | Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료 |
| US12016847B2 (en) | 2021-03-12 | 2024-06-25 | Bristol-Myers Squibb Company | Methods of treating prostate cancer |
| KR102708701B1 (ko) * | 2021-12-27 | 2024-09-24 | 에이치케이이노엔 주식회사 | 벤즈이미다졸 유도체의 제조방법 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1623984A (zh) | 1999-12-27 | 2005-06-08 | 日本烟草产业株式会社 | 稠环化合物及其药物用途 |
| DE60113809T2 (de) | 2000-01-18 | 2006-06-22 | Schering Ag | Pharmazeutische kombination aus mikronisiertem drospirenon und einen estrogen für die hormonersatztherapie |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| JP2005533756A (ja) | 2002-04-12 | 2005-11-10 | ファイザー株式会社 | Ｉｌ−６関連疾病の治療におけるｅｐ４レセプターリガンドの使用 |
| CA2492305A1 (en) * | 2002-07-31 | 2004-02-05 | Euro-Celtique S.A. | Aryl substituted benzimidazoles and their use as sodium channel blockers |
| AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| AP1927A (en) | 2002-11-15 | 2008-12-10 | Tibotec Pharm Ltd | Substituted indolepyridinium as anti-infective compounds |
| US6949564B2 (en) | 2002-12-18 | 2005-09-27 | Pfizer Inc. | NPY-5 antagonists |
| JP5015586B2 (ja) | 2003-01-29 | 2012-08-29 | アステランド ユーケイ リミテッド | Ｅｐ４受容体アンタゴニスト |
| NZ541544A (en) | 2003-04-03 | 2008-06-30 | Neurosearch As | Benzimidazole derivatives and their use for modulating the GABAA receptor complex |
| TW200512147A (en) | 2003-07-25 | 2005-04-01 | Black Clawson Converting Machinery Inc | Method and apparatus for splicing webs |
| EA009201B1 (ru) | 2003-09-03 | 2007-12-28 | Пфайзер Инк. | Фенил - или пиридиламидные соединения в качестве антагонистов простагландина e2 |
| JP2007533723A (ja) | 2004-04-20 | 2007-11-22 | ファイザー・プロダクツ・インク | α２δリガンドを含む組合せ |
| AU2005324492B2 (en) | 2004-04-23 | 2012-06-07 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
| CA2565660C (en) | 2004-05-04 | 2009-11-03 | Pfizer Inc. | Ortho substituted aryl or heteroaryl amide compounds |
| EA200701504A1 (ru) * | 2005-01-19 | 2008-02-28 | Биолипокс Аб | Индолы, пригодные для лечения воспалений |
| WO2007121578A1 (en) | 2006-04-24 | 2007-11-01 | Merck Frosst Canada Ltd. | Indole amide derivatives as ep4 receptor antagonists |
| US7732447B2 (en) * | 2006-06-22 | 2010-06-08 | Cephalon, Inc. | Fused [d]pyridazin-7-ones |
| GB0614066D0 (en) * | 2006-07-14 | 2006-08-23 | Glaxo Group Ltd | Compounds |
| FR2904318B1 (fr) * | 2006-07-27 | 2011-02-25 | Scras | Derives de pyrimidinone et leur utilisation comme medicament |
| JP5259592B2 (ja) | 2006-08-11 | 2013-08-07 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体 |
| ES2400293T3 (es) | 2007-02-26 | 2013-04-08 | Merck Canada Inc. | Derivados de indol e indolina ciclopropilamida como antagonistas de receptores EP4 |
| DE102007011105A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Schering Pharma Aktiengesellschaft | Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose |
| US20110028463A1 (en) | 2007-07-03 | 2011-02-03 | Astellas Pharma Inc. | Amide compounds |
| EP2185534A1 (en) | 2007-08-09 | 2010-05-19 | Merck Sharp & Dohme Corp. | Process for making thiophene carboxamide derivative |
| CA2733247C (en) | 2008-08-14 | 2018-04-03 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as ep4 receptor antagonists |
| WO2010117639A2 (en) | 2009-03-31 | 2010-10-14 | The Texas A&M University System | Inhibition of prostglandin e2 receptors for the treatment of endometriosis |
| WO2010124097A2 (en) | 2009-04-22 | 2010-10-28 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
| CA2789665C (en) | 2010-02-22 | 2020-06-16 | Raqualia Pharma Inc. | Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases |
| TW201607943A (zh) * | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
-
2013
- 2013-03-12 UA UAA201506493A patent/UA115576C2/uk unknown
- 2013-12-03 KR KR1020157017666A patent/KR20150092248A/ko active IP Right Grant
- 2013-12-03 AP AP2015008463A patent/AP3862A/en active
- 2013-12-03 MA MA38146A patent/MA38146B1/fr unknown
- 2013-12-03 EA EA201591087A patent/EA028830B1/ru not_active IP Right Cessation
- 2013-12-03 PT PT137986840T patent/PT2928884T/pt unknown
- 2013-12-03 MY MYPI2015701808A patent/MY175272A/en unknown
- 2013-12-03 CA CA2893630A patent/CA2893630C/en active Active
- 2013-12-03 PE PE2015000750A patent/PE20151065A1/es active IP Right Grant
- 2013-12-03 MX MX2015007135A patent/MX2015007135A/es active IP Right Grant
- 2013-12-03 ES ES13798684.0T patent/ES2637738T3/es active Active
- 2013-12-03 BR BR112015012555-7A patent/BR112015012555B1/pt active IP Right Grant
- 2013-12-03 EP EP13798684.0A patent/EP2928884B1/de active Active
- 2013-12-03 SI SI201330742T patent/SI2928884T1/sl unknown
- 2013-12-03 NZ NZ707825A patent/NZ707825A/en unknown
- 2013-12-03 JP JP2015545771A patent/JP6367822B2/ja active Active
- 2013-12-03 DK DK13798684.0T patent/DK2928884T3/en active
- 2013-12-03 LT LTEP13798684.0T patent/LT2928884T/lt unknown
- 2013-12-03 US US14/649,896 patent/US9708311B2/en active Active
- 2013-12-03 WO PCT/EP2013/075309 patent/WO2014086739A1/de active Application Filing
- 2013-12-03 AU AU2013354226A patent/AU2013354226B2/en active Active
- 2013-12-03 RS RS20170790A patent/RS56121B1/sr unknown
- 2013-12-03 ME MEP-2017-181A patent/ME02950B/me unknown
- 2013-12-03 CN CN201380063594.4A patent/CN104854098B/zh active Active
- 2013-12-03 PL PL13798684T patent/PL2928884T3/pl unknown
- 2013-12-04 JO JOP/2013/0349A patent/JO3431B1/ar active
- 2013-12-06 TW TW102144979A patent/TWI613198B/zh not_active IP Right Cessation
- 2013-12-06 AR ARP130104542A patent/AR093840A1/es unknown
- 2013-12-06 UY UY0001035177A patent/UY35177A/es unknown
-
2015
- 2015-05-27 IL IL239026A patent/IL239026A0/en active IP Right Grant
- 2015-06-04 CL CL2015001508A patent/CL2015001508A1/es unknown
- 2015-06-04 CU CU2015000056A patent/CU20150056A7/es unknown
- 2015-06-05 PH PH12015501289A patent/PH12015501289B1/en unknown
- 2015-06-05 EC ECIEPI201522555A patent/ECSP15022555A/es unknown
- 2015-06-05 TN TNP2015000250A patent/TN2015000250A1/fr unknown
- 2015-06-05 GT GT201500138A patent/GT201500138A/es unknown
- 2015-06-05 CR CR20150296A patent/CR20150296A/es unknown
- 2015-06-05 NI NI201500077A patent/NI201500077A/es unknown
- 2015-10-29 HK HK15110717.4A patent/HK1210139A1/xx unknown
-
2017
- 2017-08-04 HR HRP20171200TT patent/HRP20171200T1/hr unknown
- 2017-08-10 CY CY20171100862T patent/CY1119200T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR093840A1 (es) | Derivados de bencimidazol como antagonistas de ep4 | |
| CY1125042T1 (el) | Νεα ετεροκυκλικα παραγωγα χρησιμα ως αναστολεις shp2 | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| CO2017011754A2 (es) | Amidas heterocíclicas como inhibidores de quinasa | |
| AR091272A1 (es) | Pirazolopirimidona y pirazolopiridona como inhibidores de tanquirasa | |
| EA201892710A1 (ru) | Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa | |
| PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| EA201691302A1 (ru) | Новые гетероциклические соединения | |
| CU20160162A7 (es) | Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen | |
| PE20170664A1 (es) | Agonistas del receptor de apelina(apj) y usos de los mismos | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| PE20151752A1 (es) | Amidas heterociclicas como inhibidores de cinasas | |
| AR098843A1 (es) | Derivados de bencimidazol como ligandos de ep4 | |
| AR095423A1 (es) | 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| DK3357922T3 (da) | 2-((5-(1-(3-(methylsulfonyl)propyl)piperidin-4-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8h)-on-derivater og relaterede forbindelser som cdk4-inhibitorer til behandling af tumorer | |
| AR093468A1 (es) | Derivados de piridina | |
| AR096149A1 (es) | Macrociclos como inhibidores de quinasa | |
| AR091208A1 (es) | Derivados de piperidina | |
| EA201600436A1 (ru) | Кристаллическая солевая форма (s)-(2-(6-хлор-7-метил-1h-бензо[d]имидазол-2-ил)-2-метилпирролидин-1-ил)(5-метокси-2-(2h-1,2,3-триазол-2-ил)фенил)метанона и ее применение в качестве антагонистов орексинового рецептора | |
| AR093035A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| CL2016001342A1 (es) | Formas cristalinas hemihidrato y anhidrato de (s)-(2-(6-cloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona; composición farmacéutica que las comprende; y su uso para el tratamiento o prevención de trastornos del sueño, tales como disomnias, parasomnias, entre otras. | |
| AR102266A1 (es) | Inhibidores de aldosterona sintasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |